A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
about
Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic ReviewPotential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected PatientsSwitch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeMulticentre clinical trials' data management: a hybrid solution to exploit the strengths of electronic data capture and electronic health records systems.Autoimmune diseases and HIV infection: A cross-sectional study.Predictors of Standard Follow-Up Completion after Sexual Exposure to HIV: Five-Year Retrospective Analysis in a French HIV-Infection Care CenterLong-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.The ligurian human immunodeficiency virus clinical network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials.Imputation of the Date of HIV Seroconversion in a Cohort of Seroprevalent Subjects: Implications for Analysis of Late HIV Diagnosis.Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort StudyLong-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.HMGB1 Is Involved in IFN-α Production and TRAIL Expression by HIV-1-Exposed Plasmacytoid Dendritic Cells: Impact of the Crosstalk with NK CellsVirological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.Hepatitis C treatment initiation in HIV-HCV coinfected patients.CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cART.Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal ApproachCOPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated.Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study.First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load.Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy?No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France.Factors associated with the level of CD4 cell counts at HIV diagnosis in a French cohort: a quantile regression approach.Ageing with HIV: do comorbidities and polymedication drive treatment optimization?Characteristics and consequences of medical care interruptions in HIV-infected patients in France.How long do physicians wait to start antiretroviral treatment in newly diagnosed HIV-infected patients?Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.New Surge of Syphilis among Patients Living with Human Immunodeficiency Virus in Martinique in 2015.HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND).Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease.Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy.Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study.Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.Country of infection among HIV-infected patients born abroad living in French Guiana.Derivation and internal validation of a mortality risk index for aged people living with HIV: The Dat'AIDS score.An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients.
P2860
Q26773961-46CB7D62-A09C-4298-A561-5AA8A82B52B3Q28550423-CAFF9921-26A9-4526-BFF4-FC1C30A7E9ADQ28553066-5ED72192-B9D7-41FA-9815-C740AB094A06Q30662297-D1A466FB-8733-4367-A69D-87A61A499E62Q33438706-05472D4F-96AF-439E-8D6C-6249370D8496Q33446393-8D6BC84B-DE95-40BD-8CDE-DDFF42A246EFQ33595432-A57431CA-9F3F-4E36-92BE-8D3B1034B171Q33855379-B8680B16-2B6D-467C-B208-B46A51C2A2F9Q35370502-8840BE3A-D435-4305-B888-D1402840D186Q35814594-A2B3E604-AA58-41FF-9F66-48327807CF38Q35841996-56ED7B05-B78B-483B-A542-F3BBDE45432BQ35922101-5FF6797F-B7CA-4F59-8B0D-6FD911C66989Q35999442-17B4A28A-96FC-4743-8A65-090CB2EEC96CQ36083688-353E5590-7CCD-4851-BC1F-A331F670C406Q36185688-BCACE00C-E0A0-4347-8299-426E05D44912Q36195887-2AF1CDF9-004B-4D83-87E2-DB722AC70F90Q36240320-9199993C-2020-4F83-B438-C261118B3E3BQ36267762-5607025F-67E7-46A0-A8CB-C95A48FE9DDFQ37354804-67D59D43-D16A-4E95-B4A7-A3634A266E96Q38379391-3380905F-D465-448D-BA5A-EDF77FEA922AQ38422291-09825F19-DE3B-456B-B3A5-5308983F07B2Q38611767-4128F56E-1232-430B-B978-EC66D25E62B8Q38924001-239804F8-33D7-4E1A-BC55-D1EDA64EF13DQ38958705-C0B82A7A-B158-44B2-A585-A6BA2E5284B1Q38958712-E049A03B-2768-4997-AFFD-B20BC2BCC29DQ38958720-D248A216-E49D-4634-AC70-B4F1ED05BC4EQ39005718-0B540310-52DA-4F32-BF66-A8A41CDD489DQ40078285-E68A3667-6C17-4C91-BE90-244D50241013Q40322637-A1C41023-9C97-4ABA-AAE4-7D13B9C23FBCQ40747316-106484EB-FC95-4437-B25F-F4660F76B67EQ40836288-9C821B3D-1E6C-47A2-9AF6-20F6F4F4FC58Q42211662-4A12FB12-489E-4E98-8369-858C05C9273DQ42263784-3620CC70-6048-4B76-8AF1-480BEC3309E7Q45326406-117D9CA0-899F-41D1-AFF8-EB58AE1FA6B0Q47094903-C1C230EA-932E-4530-9179-547C58AE09BAQ47111919-F010CCAA-FEB8-4674-ACC4-6A01107C4B9CQ47800071-8752938F-3ED4-45CF-9B21-C0063798AFC0Q50053597-F4D2AD40-1295-4632-8DB6-8E7667D21AD5Q54232376-629B738C-68F8-4251-B292-D1E7E93C073DQ54475515-D32D30A6-F007-4A3E-BC58-77C9E8824D04
P2860
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
@en
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
@nl
type
label
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
@en
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
@nl
prefLabel
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
@en
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
@nl
P2093
P50
P1433
P1476
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
@en
P2093
Claudine Duvivier
Clotilde Allavena
Lise Cuzin
M A Valantin
Myriam El Guedj
Nadis Group
P Dellamonica
Pascal Pugliese
Xavier de la Tribonnière
P304
P356
10.1111/J.1468-1293.2009.00719.X
P577
2009-05-19T00:00:00Z